Omeros (NASDAQ:OMER) Earns Buy Rating from HC Wainwright

Omeros (NASDAQ:OMER – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $33.00 price objective on the biopharmaceutical company’s stock. HC Wainwright‘s price objective indicates a potential upside of 126.80% from the company’s current price. HC Wainwright also issued estimates for Omeros’ FY2027 earnings at $0.33 EPS.

A number of other equities analysts also recently issued reports on OMER. Cantor Fitzgerald reissued an “overweight” rating and set a $22.00 target price on shares of Omeros in a research note on Wednesday, October 14th. Wall Street Zen upgraded Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings upgraded Omeros from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $30.33.

Check Out Our Latest Report on OMER

Omeros Stock Up 4.5%

Shares of Omeros stock opened at $14.55 on Tuesday. Omeros has a 52-week low of $6.70 and a 52-week high of $21.24. The company’s 50-day simple moving average is $18.02 and its 200-day simple moving average is $13.79. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of 15.16 and a beta of 2.96.

Omeros (NASDAQ:OMER – Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.04. The firm had revenue of $35.93 million for the quarter, compared to analysts’ expectations of $37.28 million. Equities research analysts anticipate that Omeros will post -0.37 EPS for the current year.

Insider Activity

In other news, Director Arnold Hanish sold 10,000 shares of the stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $18.95, for a total value of $189,500.00. Following the completion of the transaction, the director owned 5,000 shares in the company, valued at $94,750. This trade represents a 66.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO David Borges sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, September 23rd. The shares were sold at an average price of $20.95, for a total transaction of $209,500.00. Following the completion of the sale, the chief accounting officer owned 5,000 shares of the company’s stock, valued at $104,750. This trade represents a 66.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 85,906 shares of company stock worth $1,628,205 in the last 90 days. 10.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in OMER. BlackRock Inc. acquired a new stake in shares of Omeros during the 2nd quarter valued at approximately $57,484,000. State Street Corp boosted its stake in shares of Omeros by 20.9% during the 2nd quarter. State Street Corp now owns 2,319,906 shares of the biopharmaceutical company’s stock worth $22,062,000 after acquiring an additional 400,331 shares in the last quarter. Corient Private Wealth LP purchased a new stake in shares of Omeros during the 2nd quarter worth approximately $6,274,000. Goldman Sachs Group Inc. boosted its stake in shares of Omeros by 151.6% during the 3rd quarter. Goldman Sachs Group Inc. now owns 395,032 shares of the biopharmaceutical company’s stock worth $7,521,000 after acquiring an additional 238,024 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Omeros by 57.8% in the 1st quarter. Bank of America Corp DE now owns 204,805 shares of the biopharmaceutical company’s stock worth $2,163,000 after acquiring an additional 74,997 shares during the period. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Key Omeros News

Investors following OMER have been watching these news items:

  • Positive Sentiment: HC Wainwright raised its FY2027 earnings-per-share estimate to $0.33 from $0.24, reaffirmed its Buy rating, and kept a $33 price target. HC Wainwright estimate update
  • Positive Sentiment: Cantor Fitzgerald maintained its Buy rating, while another analyst assessment cited YARTEMLEA’s commercial momentum as a reason for an upgrade. These views may help support sentiment after the selloff. Cantor Fitzgerald rating Analyst upgrade article
  • Negative Sentiment: Q3 results disappointed on revenue and included a wider loss, while a setback for YARTEMLEA in Europe added uncertainty about the drug’s growth prospects. These concerns drove a sharp decline in the shares after the results. YARTEMLEA setback and share reaction Q3 results and stock reaction

About Omeros

(Get Free Report)

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.

Recommended Stories

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.